HRP20210840T1 - Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci - Google Patents
Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci Download PDFInfo
- Publication number
- HRP20210840T1 HRP20210840T1 HRP20210840TT HRP20210840T HRP20210840T1 HR P20210840 T1 HRP20210840 T1 HR P20210840T1 HR P20210840T T HRP20210840T T HR P20210840TT HR P20210840 T HRP20210840 T HR P20210840T HR P20210840 T1 HRP20210840 T1 HR P20210840T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- pegylated interferon
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims 11
- 229920001184 polypeptide Polymers 0.000 title claims 3
- 239000013522 chelant Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 108010078233 Thymalfasin Proteins 0.000 claims 4
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 4
- 229960004231 thymalfasin Drugs 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- 229910052751 metal Inorganic materials 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- XBEQSQDCBSKCHJ-UHFFFAOYSA-N 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine Chemical compound FC1=CC=CC=C1C1=NC2=CN(CC=3N=NC(=CC=3)C=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)C=CC2=N1 XBEQSQDCBSKCHJ-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000001342 alkaline earth metals Chemical class 0.000 claims 1
- 229960000517 boceprevir Drugs 0.000 claims 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000004697 chelate complex Chemical class 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229960003804 efavirenz Drugs 0.000 claims 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 229960004525 lopinavir Drugs 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 1
- 229910001848 post-transition metal Inorganic materials 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229950004886 tegobuvir Drugs 0.000 claims 1
- 229960002935 telaprevir Drugs 0.000 claims 1
- 108010017101 telaprevir Proteins 0.000 claims 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims 1
- -1 telbuvidin Chemical compound 0.000 claims 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (9)
1. Farmaceutska formulacija koja sadrži antivirusni oligonukleotidni (ON) helatni kompleks, koji se sastoji od dva ili više ON povezana intermolekularno dvovalentnim kationom, pri čemu su dva ili više antivirusnih ON fosforotioirani, jednolančani polimeri nukleinske kiseline (NAP) odabrani od SEQ ID NO: 18 ili SEQ ID NO: 11, i najmanje jednog polipeptida odabranog iz grupe koja se sastoji od pegiliranog interferona α-2a i sintetičkog timozina α1,
i pri čemu je farmaceutska kompozicija formulirana za supkutanu administraciju ili za intravensku infuziju.
2. Farmaceutska kompozicija prema patentnom zahtjevu 1, pri čemu navedeni dvovalentni metalni kation je zemnoalkalni metal, prelazni metal, metal lantanida ili postprelazni metal sa 2+ stanjem naboja.
3. Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2, pri čemu navedeni dvovalentni metalni kation je kalcij, magnezij, željezo (2+), mangan, bakar ili cink.
4. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-3, koja dalje sadrži jedan ili više od sljedećih: entekavir, tenofovir dizoproksil fumarat, telbuvidin, adefovir dipivoksil, lamivudin, ribavirin, telaprevir, boceprevir, GS-7977, tegobuvir, zanamivir, oseltamivir, ganciklovir, foskarnet, aciklovir, zidovudin, abakavir, lopinavir, ritonavir ili efavirenz.
5. Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-4, koja dalje sadrži nosač.
6. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 1 koja sadrži
a) ON helatni kompleks koji sadrži oligonukleotid koji se sastoji od SEQ ID NO: 18, i pegiliranog interferona α-2a,
b) ON helatni kompleks koji sadrži oligonukleotid koji se sastoji od SEQ ID NO: 11, i pegiliranog interferona α-2a,
c) ON helatni kompleks koji sadrži oligonukleotid koji se sastoji od SEQ ID NO: 18, i sintetičkog timozina α1, ili
d) ON helatni kompleks koji sadrži oligonukleotid koji se sastoji od SEQ ID NO: 11, i sintetičkog timozina α1.
7. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1-6 za primjenu u terapiji.
8. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1-6 za primjenu u postupku liječenja virusne infekcije.
9. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 1, pri čemu su dva ili više antivirusna ON fosforotioirani, jednolančani polimeri nukleinske kiseline (NAP) sa SEQ ID NO: 18, a najmanje jedan polipeptid odabran iz grupe koja se sastoji od pegiliranog interferona α-2a i sintetičkog timozina α1, za primjenu u postupku liječenja hepatitisa B.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648711P | 2012-05-18 | 2012-05-18 | |
US201261695035P | 2012-08-30 | 2012-08-30 | |
EP13791618.5A EP2849798B1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
PCT/CA2013/050379 WO2013170386A1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210840T1 true HRP20210840T1 (hr) | 2021-08-06 |
Family
ID=49581470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210840TT HRP20210840T1 (hr) | 2012-05-18 | 2021-05-26 | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci |
Country Status (34)
Country | Link |
---|---|
US (1) | US9492506B2 (hr) |
EP (1) | EP2849798B1 (hr) |
JP (1) | JP2015517504A (hr) |
KR (1) | KR102068109B1 (hr) |
CN (1) | CN104349793B (hr) |
AU (1) | AU2013262416B2 (hr) |
BR (1) | BR112014028654A2 (hr) |
CA (1) | CA2873529C (hr) |
CL (1) | CL2014003134A1 (hr) |
CO (1) | CO7131387A2 (hr) |
CR (1) | CR20140527A (hr) |
CY (1) | CY1124345T1 (hr) |
DK (1) | DK2849798T3 (hr) |
DO (1) | DOP2014000264A (hr) |
EA (1) | EA035967B1 (hr) |
EC (1) | ECSP14027694A (hr) |
ES (1) | ES2873844T3 (hr) |
HK (1) | HK1204279A1 (hr) |
HR (1) | HRP20210840T1 (hr) |
HU (1) | HUE054875T2 (hr) |
IL (1) | IL235548B (hr) |
LT (1) | LT2849798T (hr) |
MX (1) | MX346239B (hr) |
MY (1) | MY168778A (hr) |
NZ (1) | NZ703095A (hr) |
PH (1) | PH12014502551A1 (hr) |
PL (1) | PL2849798T3 (hr) |
PT (1) | PT2849798T (hr) |
RS (1) | RS62030B1 (hr) |
SG (1) | SG11201407599SA (hr) |
SI (1) | SI2849798T1 (hr) |
TW (1) | TWI635864B (hr) |
WO (1) | WO2013170386A1 (hr) |
ZA (1) | ZA201408674B (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
NZ705730A (en) | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
HRP20231400T1 (hr) * | 2014-07-10 | 2024-02-16 | Replicor Inc. | Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d |
US10287583B2 (en) | 2014-08-15 | 2019-05-14 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
PE20211783A1 (es) * | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2769114B2 (ja) * | 1993-10-29 | 1998-06-25 | サイクローン・ファーマシューティカルズ | ミニマルb型肝炎感染症治療用医薬組成物 |
UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
EP2330194A3 (en) * | 2002-09-13 | 2011-10-12 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
JP2006519235A (ja) * | 2003-02-26 | 2006-08-24 | インターミューン インコーポレイティッド | ポリエチレングリコール修飾インターフェロン組成物およびその使用方法 |
DE602004018363D1 (de) * | 2003-10-27 | 2009-01-22 | Vertex Pharma | Kombinationen für die hcv-behandlung |
AU2005297376A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor Inc. | Antiviral oligonucleotides |
WO2007022642A2 (en) * | 2005-08-25 | 2007-03-01 | Replicor Inc. | Anti-inflammatory molecules and their uses |
CA2624686A1 (en) * | 2005-09-29 | 2007-04-05 | Replicor Inc. | Therapeutic molecules and their uses |
US7776818B2 (en) * | 2005-09-29 | 2010-08-17 | S-Cell Biosciences, Inc. | Methods to treat T-cell disorders using TISF |
GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
WO2009076679A2 (en) | 2007-12-13 | 2009-06-18 | Alnylam Pharmaceuticals Inc. | Methods and compositions for prevention or treatment of rsv infection |
AU2009221064B2 (en) * | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
JP5960049B2 (ja) * | 2009-05-28 | 2016-08-02 | クルナ・インコーポレーテッド | 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療 |
BR112012008865A2 (pt) * | 2009-10-16 | 2019-09-24 | Glaxo Group Ltd | inibidores de hbv anti-sentido. |
HUE029521T2 (en) * | 2010-08-20 | 2017-03-28 | Replicor Inc | Oligonucleotide chelate complexes |
NZ705730A (en) | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2013
- 2013-05-17 US US13/896,510 patent/US9492506B2/en active Active
- 2013-05-17 PT PT137916185T patent/PT2849798T/pt unknown
- 2013-05-17 SG SG11201407599SA patent/SG11201407599SA/en unknown
- 2013-05-17 HU HUE13791618A patent/HUE054875T2/hu unknown
- 2013-05-17 KR KR1020147035252A patent/KR102068109B1/ko active IP Right Grant
- 2013-05-17 MY MYPI2014003189A patent/MY168778A/en unknown
- 2013-05-17 WO PCT/CA2013/050379 patent/WO2013170386A1/en active Application Filing
- 2013-05-17 TW TW102117594A patent/TWI635864B/zh active
- 2013-05-17 LT LTEP13791618.5T patent/LT2849798T/lt unknown
- 2013-05-17 CA CA2873529A patent/CA2873529C/en active Active
- 2013-05-17 DK DK13791618.5T patent/DK2849798T3/da active
- 2013-05-17 EP EP13791618.5A patent/EP2849798B1/en active Active
- 2013-05-17 AU AU2013262416A patent/AU2013262416B2/en active Active
- 2013-05-17 MX MX2014014021A patent/MX346239B/es active IP Right Grant
- 2013-05-17 EA EA201401278A patent/EA035967B1/ru unknown
- 2013-05-17 PL PL13791618T patent/PL2849798T3/pl unknown
- 2013-05-17 JP JP2015511877A patent/JP2015517504A/ja active Pending
- 2013-05-17 SI SI201331881T patent/SI2849798T1/sl unknown
- 2013-05-17 ES ES13791618T patent/ES2873844T3/es active Active
- 2013-05-17 RS RS20210674A patent/RS62030B1/sr unknown
- 2013-05-17 CN CN201380026009.3A patent/CN104349793B/zh active Active
- 2013-05-17 BR BR112014028654A patent/BR112014028654A2/pt active Search and Examination
- 2013-05-17 NZ NZ703095A patent/NZ703095A/en unknown
-
2014
- 2014-11-06 IL IL235548A patent/IL235548B/en active IP Right Grant
- 2014-11-14 PH PH12014502551A patent/PH12014502551A1/en unknown
- 2014-11-18 CL CL2014003134A patent/CL2014003134A1/es unknown
- 2014-11-18 DO DO2014000264A patent/DOP2014000264A/es unknown
- 2014-11-18 CR CR20140527A patent/CR20140527A/es unknown
- 2014-11-18 EC ECIEPI201427694A patent/ECSP14027694A/es unknown
- 2014-11-19 CO CO14254322A patent/CO7131387A2/es unknown
- 2014-11-25 ZA ZA2014/08674A patent/ZA201408674B/en unknown
-
2015
- 2015-05-21 HK HK15104859.5A patent/HK1204279A1/xx unknown
-
2021
- 2021-05-26 HR HRP20210840TT patent/HRP20210840T1/hr unknown
- 2021-05-31 CY CY20211100467T patent/CY1124345T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210840T1 (hr) | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci | |
HRP20161333T1 (hr) | Kompleksi oligonukleotidnih kelata | |
De Clercq | A 40-year journey in search of selective antiviral chemotherapy | |
De Clercq | Antivirals: past, present and future | |
AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
Zhang et al. | Current prodrug strategies for improving oral absorption of nucleoside analogues | |
JP2017521433A5 (hr) | ||
ES2624353T3 (es) | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae | |
MX2018010805A (es) | Agentes antivirales contra la hepatitis b. | |
FI3166615T3 (fi) | Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi | |
HRP20211448T1 (hr) | Alfa4beta7 integrin tioeter peptidni antagonisti | |
PH12018550207A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
JP2013521279A5 (hr) | ||
BR112014003420A2 (pt) | hemifumarato de tenofovir alafenamida | |
JP2015517504A5 (hr) | ||
HRP20220911T1 (hr) | Sastav nukleotida i nukleozida i njihova uporaba | |
JP2015528449A5 (hr) | ||
De Clercq | Antiviral drug discovery: ten more compounds, and ten more stories (part B) | |
WO2015042308A3 (en) | Rna-based hiv inhibitors | |
HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
WO2014036806A8 (zh) | 一种具有草甘膦耐性的基因及其应用 | |
JP2014532722A5 (hr) | ||
NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
WO2016055534A3 (en) | Combination therapy of hbv and hdv infection | |
HRP20211197T1 (hr) | Rekombinantni glikoproteini i njihova uporaba |